http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 27 Jul 2026 20:00:15 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/Devonian+Health+Group+plans+NYSE+American+listing+and+share+offering/26820797.html <p>Devonian Health Group Inc. (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company based in Quebec, Canada, announced plans to conduct an underwritten public offering of common shares and warrants, concurrent with a proposed listing on the NYSE American LLC.</p> <p>The company expects its common shares and warrants to trade on the NYSE American under the symbols "DHGR" and "DHGRW," respectively, subject to final authorization of its listing application and continued compliance with exchange rules. No offering size or terms were disclosed in the announcement.</p> <p>ThinkEquity is serving as the sole book-running manager for the offering. A registration statement has been filed with http://www.streetinsider.com/Equity+Offerings/Devonian+Health+Group+plans+NYSE+American+listing+and+share+offering/26820797.html Mon, 27 Jul 2026 20:00:15 -0400 A.19657706 DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/Equity+Offerings/Devonian+Health+Group+plans+NYSE+American+listing+and+share+offering/26820797.html <p>Devonian Health Group Inc. (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company based in Quebec, Canada, announced plans to conduct an underwritten public offering of common shares and warrants, concurrent with a proposed listing on the NYSE American LLC.</p> <p>The company expects its common shares and warrants to trade on the NYSE American under the symbols "DHGR" and "DHGRW," respectively, subject to final authorization of its listing application and continued compliance with exchange rules. No offering size or terms were disclosed in the announcement.</p> <p>ThinkEquity is serving as the sole book-running manager for the offering. A registration statement has been filed with http://www.streetinsider.com/Equity+Offerings/Devonian+Health+Group+plans+NYSE+American+listing+and+share+offering/26820797.html Mon, 27 Jul 2026 20:00:15 -0400 A.19657706 DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/Equity+Offerings/Devonian+Health+Group+plans+NYSE+American+listing+and+share+offering/26820797.html <p>Devonian Health Group Inc. (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company based in Quebec, Canada, announced plans to conduct an underwritten public offering of common shares and warrants, concurrent with a proposed listing on the NYSE American LLC.</p> <p>The company expects its common shares and warrants to trade on the NYSE American under the symbols "DHGR" and "DHGRW," respectively, subject to final authorization of its listing application and continued compliance with exchange rules. No offering size or terms were disclosed in the announcement.</p> <p>ThinkEquity is serving as the sole book-running manager for the offering. A registration statement has been filed with http://www.streetinsider.com/Equity+Offerings/Devonian+Health+Group+plans+NYSE+American+listing+and+share+offering/26820797.html Mon, 27 Jul 2026 20:00:15 -0400 A.19657706 DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/Equity+Offerings/Devonian+Health+Group+plans+NYSE+American+listing+and+share+offering/26820797.html <p>Devonian Health Group Inc. (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company based in Quebec, Canada, announced plans to conduct an underwritten public offering of common shares and warrants, concurrent with a proposed listing on the NYSE American LLC.</p> <p>The company expects its common shares and warrants to trade on the NYSE American under the symbols "DHGR" and "DHGRW," respectively, subject to final authorization of its listing application and continued compliance with exchange rules. No offering size or terms were disclosed in the announcement.</p> <p>ThinkEquity is serving as the sole book-running manager for the offering. A registration statement has been filed with http://www.streetinsider.com/Equity+Offerings/Devonian+Health+Group+plans+NYSE+American+listing+and+share+offering/26820797.html Mon, 27 Jul 2026 20:00:15 -0400 A.19657706 DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/Equity+Offerings/Devonian+Health+Group+plans+NYSE+American+listing+and+share+offering/26820797.html <p>Devonian Health Group Inc. (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company based in Quebec, Canada, announced plans to conduct an underwritten public offering of common shares and warrants, concurrent with a proposed listing on the NYSE American LLC.</p> <p>The company expects its common shares and warrants to trade on the NYSE American under the symbols "DHGR" and "DHGRW," respectively, subject to final authorization of its listing application and continued compliance with exchange rules. No offering size or terms were disclosed in the announcement.</p> <p>ThinkEquity is serving as the sole book-running manager for the offering. A registration statement has been filed with http://www.streetinsider.com/Equity+Offerings/Devonian+Health+Group+plans+NYSE+American+listing+and+share+offering/26820797.html Mon, 27 Jul 2026 20:00:15 -0400 A.19657706 DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/Equity+Offerings/Devonian+Health+Group+plans+NYSE+American+listing+and+share+offering/26820797.html <p>Devonian Health Group Inc. (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company based in Quebec, Canada, announced plans to conduct an underwritten public offering of common shares and warrants, concurrent with a proposed listing on the NYSE American LLC.</p> <p>The company expects its common shares and warrants to trade on the NYSE American under the symbols "DHGR" and "DHGRW," respectively, subject to final authorization of its listing application and continued compliance with exchange rules. No offering size or terms were disclosed in the announcement.</p> <p>ThinkEquity is serving as the sole book-running manager for the offering. A registration statement has been filed with http://www.streetinsider.com/Equity+Offerings/Devonian+Health+Group+plans+NYSE+American+listing+and+share+offering/26820797.html Mon, 27 Jul 2026 20:00:15 -0400 A.19657706 DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/Equity+Offerings/Devonian+Health+Group+plans+NYSE+American+listing+and+share+offering/26820797.html <p>Devonian Health Group Inc. (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company based in Quebec, Canada, announced plans to conduct an underwritten public offering of common shares and warrants, concurrent with a proposed listing on the NYSE American LLC.</p> <p>The company expects its common shares and warrants to trade on the NYSE American under the symbols "DHGR" and "DHGRW," respectively, subject to final authorization of its listing application and continued compliance with exchange rules. No offering size or terms were disclosed in the announcement.</p> <p>ThinkEquity is serving as the sole book-running manager for the offering. A registration statement has been filed with http://www.streetinsider.com/Equity+Offerings/Devonian+Health+Group+plans+NYSE+American+listing+and+share+offering/26820797.html Mon, 27 Jul 2026 20:00:15 -0400 A.19657706 DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <b><span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span></b> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the <span>NYSE American LLC</span> (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html Mon, 27 Jul 2026 20:00:00 -0400 A.19657706 DHGR DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <b><span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span></b> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the <span>NYSE American LLC</span> (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html Mon, 27 Jul 2026 20:00:00 -0400 A.19657706 DHGR DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <b><span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span></b> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the <span>NYSE American LLC</span> (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html Mon, 27 Jul 2026 20:00:00 -0400 A.19657706 DHGR DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <b><span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span></b> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the <span>NYSE American LLC</span> (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html Mon, 27 Jul 2026 20:00:00 -0400 A.19657706 DHGR DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <b><span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span></b> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the <span>NYSE American LLC</span> (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html Mon, 27 Jul 2026 20:00:00 -0400 A.19657706 DHGR DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <b><span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span></b> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the <span>NYSE American LLC</span> (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html Mon, 27 Jul 2026 20:00:00 -0400 A.19657706 DHGR DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <b><span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span></b> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the <span>NYSE American LLC</span> (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html Mon, 27 Jul 2026 20:00:00 -0400 A.19657706 DHGR DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <b><span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span></b> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the <span>NYSE American LLC</span> (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html Mon, 27 Jul 2026 20:00:00 -0400 A.19657706 DHGR DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/PRNewswire/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <b><span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span></b> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the <span>NYSE American LLC</span> (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of http://www.streetinsider.com/PRNewswire/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html Mon, 27 Jul 2026 20:00:00 -0400 A.19657706 DHGR DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/PRNewswire/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <b><span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span></b> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the <span>NYSE American LLC</span> (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of http://www.streetinsider.com/PRNewswire/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html Mon, 27 Jul 2026 20:00:00 -0400 A.19657706 DHGR DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/PRNewswire/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <b><span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span></b> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the <span>NYSE American LLC</span> (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of http://www.streetinsider.com/PRNewswire/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html Mon, 27 Jul 2026 20:00:00 -0400 A.19657706 DHGR DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/PRNewswire/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <b><span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span></b> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the <span>NYSE American LLC</span> (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of http://www.streetinsider.com/PRNewswire/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html Mon, 27 Jul 2026 20:00:00 -0400 A.19657706 DHGR DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/PRNewswire/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <b><span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span></b> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the <span>NYSE American LLC</span> (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of http://www.streetinsider.com/PRNewswire/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html Mon, 27 Jul 2026 20:00:00 -0400 A.19657706 DHGR DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/PRNewswire/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <b><span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span></b> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the <span>NYSE American LLC</span> (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of http://www.streetinsider.com/PRNewswire/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html Mon, 27 Jul 2026 20:00:00 -0400 A.19657706 DHGR DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/PRNewswire/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <b><span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span></b> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the <span>NYSE American LLC</span> (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of http://www.streetinsider.com/PRNewswire/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html Mon, 27 Jul 2026 20:00:00 -0400 A.19657706 DHGR DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/PRNewswire/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <b><span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span></b> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the <span>NYSE American LLC</span> (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of http://www.streetinsider.com/PRNewswire/Devonian+Health+Group+Announces+Proposed+Listing+on+the+NYSE+American+with+Concurrent+Underwritten+Public+Offering/26820796.html Mon, 27 Jul 2026 20:00:00 -0400 A.19657706 DHGR DHGR DHGRW DVHGF GSD O.36250936 O.47005133 http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Receives+Health+Canada+Authorization+to+Initiate+Phase+IIIII+Pediatric+Clinical+Trial+of+Thykamine%E2%84%A2+for+Mild-to-Moderate+Atopic+Dermatitis+in+Patients+Aged+3+Months+to+17+Year/26792942.html <div class="xn-content"> <div class="fr-subtext"><ul type="disc"> <li><i>The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment. </i></li> <li><i>Secondary objectives include assessment of the overall safety and tolerability.</i></li> <li><i>The trial will employ a seamless adaptive Phase II/III design, incorporating an interim analysis following completion of Phase II to allow a seamless transition into the confirmatory Phase III portion of the program.</i></li> <li><i>Devonian believes Thykamine™ has the potential to provide an important new non-steroidal therapeutic option for pediatric patients requiring long-term disease management.</i></li> </ul></div><p><span http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Receives+Health+Canada+Authorization+to+Initiate+Phase+IIIII+Pediatric+Clinical+Trial+of+Thykamine%E2%84%A2+for+Mild-to-Moderate+Atopic+Dermatitis+in+Patients+Aged+3+Months+to+17+Year/26792942.html Tue, 21 Jul 2026 08:45:00 -0400 A.17150087 A.60012013 DVHGF GSD O.34929518 O.47005133 O.54379156 http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Receives+Health+Canada+Authorization+to+Initiate+Phase+IIIII+Pediatric+Clinical+Trial+of+Thykamine%E2%84%A2+for+Mild-to-Moderate+Atopic+Dermatitis+in+Patients+Aged+3+Months+to+17+Year/26792942.html <div class="xn-content"> <div class="fr-subtext"><ul type="disc"> <li><i>The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment. </i></li> <li><i>Secondary objectives include assessment of the overall safety and tolerability.</i></li> <li><i>The trial will employ a seamless adaptive Phase II/III design, incorporating an interim analysis following completion of Phase II to allow a seamless transition into the confirmatory Phase III portion of the program.</i></li> <li><i>Devonian believes Thykamine™ has the potential to provide an important new non-steroidal therapeutic option for pediatric patients requiring long-term disease management.</i></li> </ul></div><p><span http://www.streetinsider.com/Press+Releases/Devonian+Health+Group+Receives+Health+Canada+Authorization+to+Initiate+Phase+IIIII+Pediatric+Clinical+Trial+of+Thykamine%E2%84%A2+for+Mild-to-Moderate+Atopic+Dermatitis+in+Patients+Aged+3+Months+to+17+Year/26792942.html Tue, 21 Jul 2026 08:45:00 -0400 A.17150087 A.60012013 DVHGF GSD O.34929518 O.47005133 O.54379156